In Immunology, J&J Makes A Big Move On Biologic Combinations

 
• By Jessica Merrill

The company has initiated a Phase II study of Tremfya and Simponi in combination for the treatment of ulcerative colitis, J&J's first human study of two targeted immunology drugs together. 

Vial Separation Turntable
J&J will have to keep an eye on safety

More from Clinical Trials

More from R&D